| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline | 
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt | 
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current | 
|---|
                                    
                                U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Shares of Acelyrin, Inc. (NASDAQ:SLRN) fell sharply in today's pre-market trading.
ACELYRIN announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.
Acelyrin shares tumbled 15.4% to $2.95 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
Now Read This: